FAKTOR OPTIONSSCHEIN - FATE THERAPEUTICS Share Price

Certificat

DE000GG731F6

Market Closed - Börse Stuttgart 17:45:32 31/05/2024 BST
2.98 EUR +15.06% Intraday chart for FAKTOR OPTIONSSCHEIN - FATE THERAPEUTICS
Current month-64.01%
1 month-64.01%
Date Price Change
31/05/24 2.98 +15.06%
30/05/24 2.59 -8.16%
29/05/24 2.82 -8.14%
28/05/24 3.07 -0.32%
27/05/24 3.08 -1.28%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 05:45 pm

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying FATE THERAPEUTICS, INC.
Issuer Goldman Sachs
WKN GG731F
ISINDE000GG731F6
Date issued 26/04/2024
Strike 2.76 $
Maturity Unlimited
Parity 0.24 : 1
Emission price 7.84
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 11.38
Lowest since issue 2.48
Spread 0.05
Spread %1.65%

Company Profile

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Sector
-
More about the company

Ratings for Fate Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Fate Therapeutics, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
3.68 USD
Average target price
6.643 USD
Spread / Average Target
+80.51%
Consensus